Private Placement

As it heads to key conferences, Orchestra BioMed is pitching its novel pacemaker-based hypertension treatment and a unique drug-eluting balloon.

The cannabis giant's landmark debt deal signals new institutional confidence, but a high interest rate reveals the industry's costly reality.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

With new kits for complex cell models, Atrandi's semi-permeable capsules challenge market leaders by enabling multi-step workflows previously out of reach.

The PXM leader surpassed the coveted 'Rule of 40' financial benchmark in 2025, signaling strong growth and profitability as it preps for an AI-driven future.

The firm's new SBIC fund leverages a key government partnership to inject vital capital into the U.S. lower middle-market, a critical engine for the economy.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

A groundbreaking, NIH-funded trial will use advanced PET imaging to test new Alzheimer's drugs, with XingImaging managing the critical visual data.

The Nashville-based clinic brings its luxury, results-driven skincare model to Arlington, VA, tapping into national wellness trends and rapid growth.

The firm's new growth lending fund combines non-dilutive capital with an AI focus, offering a powerful alternative to traditional venture equity for tech firms.

LandGate's new platform delivers instant, engineering-grade analysis for battery storage sites, aiming to break a key bottleneck in the energy transition.

Over 100 institutions, including BlackRock and Vanguard, now hold Chaince Digital. What's driving this quiet endorsement of a firm pivoting to AI and tokenization?

A new tech partnership simplifies solar adoption, helping companies slash emissions, lock in energy costs, and boost their bottom line.

A new fund managed by 'agentic AI' promises to outperform markets by eliminating human bias. But can we trust algorithms with our investments?

A major Nevada discovery of high-grade gold and critical antimony could bolster U.S. supply chains as global tensions over the strategic metal escalate.

Struggling lifestyle brand Greenlane appoints DeFi expert Jason Hitchcock as CEO, doubling down on its risky pivot into the Berachain ecosystem.

A new biotech emerges with massive funding and a next-gen 'shuttle' to deliver safer, more effective Alzheimer's therapies directly to the brain.

Polestar unveils a bold plan to launch four new models by 2028, but can the EV maker overcome financial hurdles and intense market competition?

Investment in Canadian fintech moderated to $2.4B in 2025, but a closer look reveals a healthy shift toward strategic AI and digital asset deals.

With a sales backlog soaring to $7.1M, the clean tech firm is raising capital and realigning leadership to scale its innovative thermal energy systems.